[an error occurred while processing this directive]
Skip to Main Content

Latest News

January 14, 2008
Volume 86, Number 2
p. 10


Isis, Genzyme In Heart Drug Deal

Cholesterol treatment further validates antisense approach to targeting RNA

Lisa Jarvis

In a major boost for antisense technology, Isis Pharmaceuticals and Genzyme have sealed a deal that could be worth nearly $2 billion for mipomersen, Isis' second-generation antisense drug. Antisense drugs target the RNA that controls the production of disease-causing proteins.

To gain access to the drug, which lowers cholesterol, Genzyme will shell out $175 million upfront and, upon closing of the deal, buy $150 million worth of Isis stock. Isis stands to receive another $825 million in development and regulatory milestones, as well as up to $750 million in commercial milestones.

Research at Isis' Carlsbad, Calif., labs has paid off.

Isis also retains a healthy level of any profits from sales of mipomersen, which the company's CEO, Stanley T. Crooke, calls its "most important asset."

Mipomersen, currently in Phase III trials in patients with familial hypercholesterolemia, is widely viewed as a potential blockbuster. Earlier trials showed it to be effective in lowering lipid levels both on its own and in combination with other drugs, and it can be given to patients who cannot tolerate statins. It also enjoys the benign side-effect profile associated with the antisense approach.

Mark Monane, a stock analyst with Needham & Co., calls the midsized Genzyme a "near optimal partner" for developing the cholesterol drug. He points to Genzyme's experience in bringing niche drugs to market, particularly in the cardiovascular category. For Isis, the most critical factor was that mipomersen "will be almost as important to Genzyme as it is to us," Crooke tells C&EN.

Drugs from the first generation of antisense technology were based on single-stranded DNA-like oligonucleotides and did not survive in the body long enough to have an impact on disease. As a result, some colossal failures in late-stage trials caused many observers to doubt the validity of the technology.

Second-generation drugs, single-stranded oligos whose backbone chemistry makes them look like both DNA and RNA, have proven more potent. Whether or not the technology is sound is "a question it's time for people to stop asking," Crooke says. Between the deal with Genzyme and earlier Isis alliances with Bristol-Myers Squibb and Johnson & Johnson, he adds, it is clear that "smart people who are looking at the data see that second-generation antisense drugs are working."

Save/Share »

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2009 American Chemical Society


Save/Share »



Our log-in process has changed. You need an ACS ID to access member-only content.



Questions or Problems?

Adjust text size:

A- A+

Articles By Topic